Your browser doesn't support javascript.
loading
Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials.
Rahman, Ruman; Janowski, Miroslaw; Killick-Cole, Clare L; Singleton, William G B; Campbell, Emma; Walczak, Piotr; Khatua, Soumen; Faltings, Lukas; Symons, Marc; Schneider, Julia R; Kwan, Kevin; Boockvar, John A; Gill, Steven S; Oliveira, J Miguel; Beccaria, Kevin; Carpentier, Alexandre; Canney, Michael; Pearl, Monica; Veal, Gareth J; Meijer, Lisethe; Walker, David A.
Afiliación
  • Rahman R; Children's Brain Tumor Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
  • Janowski M; Center for Advanced Imaging Research, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, 655 W. Baltimore Street, Baltimore, MD 21201, USA.
  • Killick-Cole CL; Functional Neurosurgery Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Level 1 Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
  • Singleton WGB; Clinical Neurosciences, Translational Health Sciences, University of Bristol & Bristol Royal Hospital for Children, Level 1 Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
  • Campbell E; Children's Brain Tumor Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
  • Walczak P; Center for Advanced Imaging Research, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, 655 W. Baltimore Street, Baltimore, MD 21201, USA.
  • Khatua S; Department of Pediatrics Hematology/Oncology, Mayo Clinic/Rochester Cancer Center, 200 First St. SW, Rochester, MN 55905, USA.
  • Faltings L; Brain Tumor Biotech Center, Department of Neurosurgery, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, 100 E 77th Street, New York, NY 10075, USA.
  • Symons M; Feinstein Institute for Medical Research, Zucker School of Medicine at Hofstra/Northwell, 350 Community Dr, Manhasset, NY 11030, USA.
  • Schneider JR; Brain Tumor Biotech Center, Department of Neurosurgery, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, 100 E 77th Street, New York, NY 10075, USA.
  • Kwan K; Brain Tumor Biotech Center, Department of Neurosurgery, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, 100 E 77th Street, New York, NY 10075, USA.
  • Boockvar JA; Brain Tumor Biotech Center, Department of Neurosurgery, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, 100 E 77th Street, New York, NY 10075, USA.
  • Gill SS; Functional Neurosurgery Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Level 1 Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
  • Oliveira JM; 3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017
  • Beccaria K; ICVS/3B's-PT Government Associate Laboratory, Largo do Paço, 4704-553 Braga, Portugal.
  • Carpentier A; APHP, Department of Pediatric Neurosurgery, Necker-Enfants Malades Hospital, 149 Rue de Sèvres, 75015 Paris, France.
  • Canney M; APHP, Department of Pediatric Neurosurgery, Necker-Enfants Malades Hospital, 149 Rue de Sèvres, 75015 Paris, France.
  • Pearl M; Carthera, Laënnec Bioparc, 60A Avenue Rockefeller, 69008 Lyon, France.
  • Veal GJ; Department of Diagnostic Imaging and Radiology, Children's National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USA.
  • Meijer L; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne NE1 7RU, UK.
  • Walker DA; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands.
Cancers (Basel) ; 15(3)2023 Jan 30.
Article en En | MEDLINE | ID: mdl-36765816
Brain and spinal tumors affect 1 in 1000 people by 25 years of age, and have diverse histological, biological, anatomical and dissemination characteristics. A mortality of 30-40% means the majority are cured, although two-thirds have life-long disability, linked to accumulated brain injury that is acquired prior to diagnosis, and after surgery or chemo-radiotherapy. Only four drugs have been licensed globally for brain tumors in 40 years and only one for children. Most new cancer drugs in clinical trials do not cross the blood-brain barrier (BBB). Techniques to enhance brain tumor drug delivery are explored in this review, and cover those that augment penetration of the BBB, and those that bypass the BBB. Developing appropriate delivery techniques could improve patient outcomes by ensuring efficacious drug exposure to tumors (including those that are drug-resistant), reducing systemic toxicities and targeting leptomeningeal metastases. Together, this drug delivery strategy seeks to enhance the efficacy of new drugs and enable re-evaluation of existing drugs that might have previously failed because of inadequate delivery. A literature review of repurposed drugs is reported, and a range of preclinical brain tumor models available for translational development are explored.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article Pais de publicación: Suiza